RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 29, 2022
Context: This filing serves as a notification to the U.S. Securities and Exchange Commission regarding the availability of the audio recording for the Q2 FY23 earnings call, the retirement of Independent Director Mr. Prasad Menon, and the filing of the Q2 FY23 Form 6-K. The registrant files annual reports under Form 20-F.

Key Financial Metrics

The provided filing text does not contain specific financial data. It is a cover document referencing exhibits rather than a financial report itself. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.

Material Changes

Corporate Governance Change:

• Mr. Prasad Menon has retired as an Independent Director (Exhibit 99.2).

Reporting Activity:

• Audio recording for the Q2 FY23 earnings call is available (Exhibit 99.1).
• Formal filing of Q2 FY23 results with the US SEC (Exhibit 99.3).

The filing text does not provide comparative financial data to assess material changes in performance versus prior periods.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or details on unusual items. These details are expected to be found in the referenced earnings call recording or the full Q2 FY23 report.

Investor Verification Checklist

• Verify the full Q2 FY23 financial results and management commentary in the referenced earnings call recording (Exhibit 99.1).
• Confirm the effective date and replacement process for the retirement of Independent Director Mr. Prasad Menon.
• Review the complete Q2 FY23 Form 6-K filing for detailed financial statements and risk disclosures not included in this cover document.